Phase 1 N=14 A Single-Dose Trial to Examine the Within Subject Variability of Clexane® in Healthy Adults Under Fasting Conditions
Clexane is Administered to Healthy Volunteers
Primary: Anti-FXa Cmax — 0.999; 0.926 IU/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=47 Bioavailability Study of Enoxaparin Sodium Chemi and Clexane s.c.
Enoxaparin Sodium is Administered to Healthy Volunteers
Primary: Cmax (Anti-FXa and Anti-FIIa) — 0.8593; 0.8698; 0.1187; 0.1296 IU/mL
Phase 1 N=42 A Study of a Single Subcutaneous Dose of ALXN1210 in Healthy Adult Participants
Healthy
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 19; 11; 5 Participants
Phase 1 N=63 A Study of LY2951742 in Healthy Volunteers
Migraines
Primary: Number of Participants With Clinically Significant Effects — 0; 0; 0; 0 participants
Phase 1 N=24 Effect of Low-Fat Food on Pexidartinib Pharmacokinetics in Healthy Volunteers
Healthy Volunteers
Primary: Maximum Observed Concentration in Plasma (Cmax) of Pexidartinib — 4580; 7090; 3870 ng/mL
Phase 1 N=16 A Study of Multiple Doses of ALXN1210 in Healthy Adult Participants
Healthy
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 6; 6; 4 Participants
Phase 4 N=10 Anti-platelet Effects of Colchicine in Healthy Volunteers
Healthy
Primary: Monocyte Platelet Aggregate: Baseline — 27.8 percentage of monocyte-platelet aggregat
Phase 1 N=62 Phase 1 Study of ELX-02 in Healthy Adult Subjects
Genetic Disease · Nonsense Mutation
Primary: Pharmacokinetic Parameters - Plasma AUC0-24 — 1105.126; 3125.484; 11018.22; 28235.823 ng*h/mL
Phase 1 N=30 A Study to Compare the Concentrations of LY2189265 After Different Methods of Administration to Healthy Volunteers.
Diabetes Mellitus, Type II
Primary: Dose Normalized Area Under the Concentration Time Curve (AUC) of LY2189265: Subcutaneous (SC) to Intravenous (IV) — 10256; 23150 nanograms*hour/milliliter/milligram
Phase 1 N=47 Single Rising Dose Study of BI 655088 Administered Intravenously in Healthy Male Volunteers
Healthy
Primary: Number of Subjects With Drug-related Adverse Events — 2; 1; 2; 1 Participants
Phase 1 N=60 Study of ALXN1820 in Healthy Adult Participants
Healthy
Primary: Number of Participants With Treatment-related Adverse Events (TEAEs) For ALXN1820 SC And ALXN1820 IV — 1; 0; 0; 4 Participants
Phase 1 N=40 A First-in-Human Study of LY3009385 in Healthy Participants
Diabetes Mellitus, Type 2
Primary: Number of Participants With One or More Drug-related Adverse Events (AEs) or Any Serious AEs — 1; 1; 1; 2 participants
Phase 1 N=18 A Study of LY2605541 in Healthy Participants
Healthy Volunteers
Primary: Pharmacokinetics: Area Under the Concentration Time Curve From Zero to Infinity (AUC[0-∞]) of LY2605541 — 128000; 145000; 135000 picomoles times hours per liter
Phase 1 N=29 A Study of LY900014 Formulations in Healthy Participants
Healthy Volunteers
Primary: Part A: Pharmacokinetics (PK ): Area Under the Concentration Curve From Zero to the Last Recorded Time Post Dose (AUC0-tlast) — 1720; 1740; 1810; 1750 picomol times hour…
Phase 2 N=107 A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects
Bleeding
Primary: Percent Change in Anti-Fxa Activity From Baseline to the End of Infusion (EOI) Nadir. — -94.50; -29.00; -98.00; -37.00 percent change — p=0.0275
Phase 1 N=14 A Study of a Single Dose of ALXN1210 in Healthy Participants
Healthy
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 3; 4; 4 Participants
Phase 1 N=36 Safety, Tolerability, and Pharmacokinetics of a Subcutaneous and Intravenous Dose of BI 655130 in Healthy Subjects
Healthy
Primary: Area Under the Concentration-time Curve of BI 655130 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 1579.19; 2204.35…
Phase 1 N=16 A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Emicizumab in Healthy Chinese Volunteers
Healthy Volunteers · Hemophilia A
Primary: Maximum Observed Plasma Concentration (Cmax) of Emicizumab — 7.11 microgram per milliliter (μg/mL)
Phase 1 N=77 Study of CD388 Intramuscular or Subcutaneous Administration in Healthy Subjects
Healthy
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) After a Single Dose of CD388 — 5; 5; 5; 8 Participants
Phase 1 N=28 A Study in Healthy Men to Test How BI 765080 is Taken up in the Body When Given as an Injection Under the Skin Compared With an Infusion Into the Vein
Healthy
Primary: Area Under the Concentration-time Curve of BI 765080 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 3528304.5; 7625263.8…
Phase 1 N=21 Safety and Tolerability Study of E-WE Thrombin in Healthy Adult Subjects
Thrombosis
Primary: The Number of Subjects With Treatment-emergent Adverse Events (TEAEs) Will be Summarized Using Frequency Counts. — 0; 0; 0; 3 Participants
Phase 1 N=24 A Study of TAK-881 in Healthy Adults
Healthy Volunteers
Primary: Number of Participants With Tolerability Events Related to Infusion of TAK-881 Per Infusion Site — 8; 8; 8; 4 Participants
Phase 4 N=62 Enoxaparin Dosing in Obesity
Obesity
Primary: Proportion of Patients With an Initial Therapeutic Anti-Xa Level at Steady State in Each Group — 25; 20 Participants
Phase 1 N=41 A Study of LY3025876 in Healthy Volunteers
Healthy Volunteers
Primary: Number of Participants With 1 or More Drug-related Adverse Events or Any Serious Adverse Events — 0; 0; 0; 0 participants
Phase 3 N=124 A Safety and Efficacy Study of BCD-080 Compared to Clexan for Deep Vein Thrombosis Prophylaxis at Orthopedic Surgeries
Deep Vein Thrombosis
Primary: Frequency of DVT. — 0; 2 participants — p=0.226
Phase 1 N=64 Safety and Pharmacokinetics of Single and Multiple Ascending Doses of 3K3A-APC in Healthy Adult Volunteers
Healthy
Primary: Adverse Events That Meet Dose-limiting Toxicity Criteria Specified in Protocol. — 0; 0; 0; 0 participants
Phase 1 N=12 Safety and Pharmacokinetics of Multiple Doses of BI 655064 in Healthy Chinese Male Volunteers
Healthy
Primary: Percentage of Subjects With Drug-related Adverse Events. — 66.7; 55.6 Percentage of subjects
Phase 1 N=64 Study to Evaluate the Safety, Tolerability, PK, and PD of PB2452 in Healthy Volunteers
Healthy
Primary: Number of Participants With Adverse Events (AEs) — 0; 0; 1; 1 Participants
Phase 1 N=28 A Study of LY900014 Formulation at Different Injection Sites in Healthy Participants
Diabetes Mellitus, Type 2
Primary: Pharmacokinetics: Insulin Lispro Area Under the Concentration Versus Time Curve (AUC) Following LY900014 Administration — 1760; 1800; 2770; 1750 picomole * hour/Liter…
Phase 1 N=48 A Study in Healthy People to Measure the Amount of BI 655130 in the Blood After Injecting Different Doses Into Different Parts of the Body
Healthy
Primary: Area Under the Concentration-time Curve of BI 655130 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 1227.91; 1150.18; 1718.47…